This is suspected to be a problem with the Oxford vaccine which also uses one virus vector for both doses.
Like Sputnik V, J&J's Janssen unit's Ebola vaccine uses two different virus vectors. And Janssen is doing an ENSEMBLE 2 Phase III clinical trial with two doses eight weeks apart that lol768 mentions. But their primary objective stated from the very beginning was to create the most effective single dose vaccine possible, and vaccinated a billion people in 2021.
They appear to have achieved the former, although Sputnik Lite with the same Ad26 based vector could be a competitor, the latter goal is failing due to inherent issues with using cell culturing to make something, a strained supply chain for that which is also required to make Oxford's Sputnik V, and Novavax's vaccine (bug cell grown protein plus adjuvant), and being forced to use the dangerously incompetent Emergent BioSolutions as a subcontractor.